Determination of RNASEH2B copy numbers in 100 patient‐derived CLL cell lines and 226 prostate cancers showed that at least one copy was lost in 57% and 36% of the respective cancer samples. This evidence concerns the gene RNASEH2B and prostate carcinoma.